78 Indeed, although placebo-treated animals progressively lost body weight, lean and fat mass, espindolol-treated animals showed increases in all these parameters without affecting cardiac

function. Key regulators of muscle catabolism showed reduced expression under espindolol treatment. Another animal study showed that the beneficial effects of espindolol on wasting were more pronounced than those of other beta-blockers.79 The ACT-ONE trial was designed to test whether MT-102 (espindolol) will positively impact the rate of change learn more of body weight in cancer cachexia. The trial’s preliminary results were recently published in abstract form.80 and 81 It enrolled a total of 87 patients with non–small cell lung cancer or colorectal cancer from

17 centers who were in stage 3 or 4 of the disease. Patients were randomized in a 3:1:2 fashion to 1 of 2 doses of espindolol (10.0 or 2.5 mg twice daily) or placebo and treated for 16 weeks. Only the higher dose of espindolol improved lean and fat mass. Hand grip strength increased significantly after 16 weeks in the low-dose and high-dose treatment groups, but stair climbing power and 6-minute walking distance did not. Muscle wasting and cachexia remain great challenges in clinical practice. Clinical trials in this field remain small, and most are undertaken in oncology patients. Much research

has PI3K Inhibitor Library order focused on appetite stimulation (mostly using megestrol acetate), anti-inflammatory pathways, and anabolics. Ghrelin has shown some potential in clinical trials as has enobosarm. Results of the POWER trial with enobosarm, one of the few large-scale trials to improve muscle mass and function in patients with advanced cancer, are eagerly awaited. In addition, results of the ACT-ONE trial using the anabolic/catabolic transforming agent espindolol have shown promising results. This paper is also published in parallel in International Journal of Cardiology. “
“The population of very old people (aged ≥85 years) is growing fantofarone rapidly, along with an increasing prevalence of hypertension.1 and 2 The association between blood pressure (BP) and mortality is not entirely understood in this population, including those with multimorbidity and those living in residential care facilities. Results of population-based studies3, 4, 5, 6, 7, 8, 9 and 10 have suggested that hypertension is not a risk factor for death in very old individuals. Antihypertensive treatment has been shown to have positive effects on cardiovascular morbidity in a systematic review11 and a large meta-analysis12 of randomized controlled trials, but neither study found any effect on overall mortality in people aged 80 years or older.